Literature DB >> 20035585

Predictive factors for persistent use and compliance of immediate-release methylphenidate: a 36-month naturalistic study.

Paola Atzori1, Tatiana Usala, Sara Carucci, Fabrice Danjou, Alessandro Zuddas.   

Abstract

AIM: The objective of this study was to evaluate predictors of long-term adherence to treatment with methylphenidate (MPH).
METHODS: A total of 134 children (ages 4-16) with a diagnosis of attention-deficit/hyperactivity disorder (ADHD) determined by specific protocols, including a semistructured parent interview, Conners' Teacher/Parent Rating Scales, cognitive and learning evaluation, and child self-reports for anxiety and depression, were assessed monthly for up to 36 months. At the end of the study (36 months), three outcomes were evaluated (continuing medication, medication withdrawn due to functional remission, and medication withdrawn for other reasons including poor compliance). Outcomes were first analyzed by mean of the chi-squared test, Mann-Whitney-U test, or t-test, and predictive models were subsequently generated using Cox proportional hazards model analysis. Age, ADHD subtype, co-morbidity, cognitive functioning, side effects, and family and social characteristics were considered as independent variables.
RESULTS: Thirty-six months after starting MPH, 62 children (46%) were still on treatment, 32 (24%) had stopped MPH due to functional remission, and 40 (30%) had suspended MPH for other reasons. Within the last group, 20 suspended for poor compliance, 10 for decrease of efficacy, 5 for side effects, and 5 because they entered in an atomoxetine clinical trial. The presence of associated disorders, younger age, female gender, and not living with both parents were predictors for continuing medication until end of the study (36 months); absence of associated disorders and older age were predictors of discontinuation medication due to functional remission before the end of study, older age, and hyperactive subtype were predictors of discontinuing medication for other reasons.
CONCLUSION: Clinical outcome of ADHD treatment is heterogeneous: Specific clinical and social predictive parameters for long-term MPH use and compliance can be identified. An accurate tailoring of clinical intervention to the individual child appears crucial for good outcome.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20035585     DOI: 10.1089/cap.2008.0146

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  21 in total

Review 1.  Achieving remission as a routine goal of pharmacotherapy in attention-deficit hyperactivity disorder.

Authors:  J Antoni Ramos-Quiroga; Miguel Casas
Journal:  CNS Drugs       Date:  2011-01       Impact factor: 5.749

2.  Stimulant Treatment of Young People in the United States.

Authors:  Mark Olfson; Marissa King; Michael Schoenbaum
Journal:  J Child Adolesc Psychopharmacol       Date:  2016-03-16       Impact factor: 2.576

3.  Omega-3/6 supplementation for mild to moderate inattentive ADHD: a randomised, double-blind, placebo-controlled efficacy study in Italian children.

Authors:  Sara Carucci; Roberta Romaniello; Giovanni Demuru; Paolo Curatolo; Clementina Grelloni; Gabriele Masi; Francesca Liboni; Alessandra Mereu; Paolo Contu; Marco Lamberti; Antonella Gagliano; Alessandro Zuddas
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-06-07       Impact factor: 5.270

4.  A Follow-up Study of Academic Functioning and Social Adjustment in Children with Attention Deficit Hyperactivity Disorder.

Authors:  Jasmin Garg; Priti Arun
Journal:  Indian J Psychol Med       Date:  2013-01

5.  Editorial: Observational studies in ADHD: the effects of switching to modified-release methylphenidate preparations on clinical outcomes and adherence.

Authors:  Aribert Rothenberger; Manfred Döpfner
Journal:  Eur Child Adolesc Psychiatry       Date:  2011-10       Impact factor: 4.785

6.  Drug therapy of attention deficit hyperactivity disorder: current trends.

Authors:  Avinash De Sousa; Gurvinder Kalra
Journal:  Mens Sana Monogr       Date:  2012-01

7.  Strategies for improving ADHD medication adherence.

Authors:  Kelly I Kamimura-Nishimura; William B Brinkman; Tanya E Froehlich
Journal:  Curr Psychiatr       Date:  2019-08

8.  Eliciting preferences for continuing medication among adult patients and parents of children with attention-deficit hyperactivity disorder.

Authors:  Muhammad Umair Khan; Camila Balbontin; Michiel C J Bliemer; Parisa Aslani
Journal:  Health Expect       Date:  2022-03-10       Impact factor: 3.318

9.  Prevalence, determinants and spectrum of attention-deficit hyperactivity disorder (ADHD) medication of children and adolescents in Germany: results of the German Health Interview and Examination Survey (KiGGS).

Authors:  Hildtraud Knopf; Heike Hölling; Michael Huss; Robert Schlack
Journal:  BMJ Open       Date:  2012-11-23       Impact factor: 2.692

Review 10.  Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies.

Authors:  Ole Jakob Storebø; Nadia Pedersen; Erica Ramstad; Maja Lærke Kielsholm; Signe Sofie Nielsen; Helle B Krogh; Carlos R Moreira-Maia; Frederik L Magnusson; Mathilde Holmskov; Trine Gerner; Maria Skoog; Susanne Rosendal; Camilla Groth; Donna Gillies; Kirsten Buch Rasmussen; Dorothy Gauci; Morris Zwi; Richard Kirubakaran; Sasja J Håkonsen; Lise Aagaard; Erik Simonsen; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2018-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.